Veru
Veru is a biopharmaceutical company that develops novel medicines for weight loss, breast cancer, and ARDS, and markets the FDA-approved FC2 Female Condom globally.
Services
Veru specializes in developing novel medicines for high-quality weight loss, breast cancer, and viral-induced ARDS. The company conducts clinical trials for enobosarm, a selective androgen receptor modulator, targeting muscle loss and breast cancer. Veru also operates a direct-to-patient telemedicine and pharmacy services portal in the U.S. for its product FC2 Female Condom, the only FDA-approved single-use internal condom for preventing pregnancy, STIs, and HIV/AIDS. The company markets its products globally, ensuring broad availability and accessibility.
Products
Veru offers several key products, including the FC2 Female Condom, which is FDA-approved and provides dual protection against unintended pregnancy and sexually transmitted infections. The FC2 Female Condom is the only single-use internal condom available by prescription covered by most U.S. insurance plans under the Affordable Care Act. Veru is also developing enobosarm for various medical conditions, including muscle loss and breast cancer, and sabizabulin for treating viral-induced acute respiratory distress syndrome (ARDS), showing positive results in COVID-19 clinical trials.
Clinical Trials and Research
Veru conducts extensive clinical trials to advance its pipeline of medicines. The company has completed positive Phase 2 and Phase 3 COVID-19 clinical trials for sabizabulin, demonstrating significant mortality benefits in hospitalized patients with moderate to severe COVID-19. Veru also researches enobosarm for its potential to augment fat loss and prevent muscle loss when used with weight loss drugs. The company seeks external funding through government grants and pharmaceutical partnerships to support its infectious disease program.
Global Presence and Distribution
Veru markets its products globally, with the FC2 Female Condom distributed in the U.S. and 149 other countries. The company has sold over 750 million female condoms worldwide. Veru also holds a significant presence in the global public health sector by marketing FC2 to entities such as ministries of health and U.N. agencies. The company's offices in Miami, London, and Malaysia facilitate its widespread distribution and international operations.